NEUROMYELITIS OPTICA
Clinical trials for NEUROMYELITIS OPTICA explained in plain language.
Never miss a new study
Get alerted when new NEUROMYELITIS OPTICA trials appear
Sign up with your email to follow new studies for NEUROMYELITIS OPTICA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise in rare nerve disease trial
Disease control CompletedThis Phase 3 trial tested the drug ravulizumab (Ultomiris) in 58 adults with neuromyelitis optica spectrum disorder (NMOSD), a rare condition where the immune system attacks the optic nerves and spinal cord. The goal was to see if the drug could prevent relapses. Participants rec…
Matched conditions: NEUROMYELITIS OPTICA
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Study reveals vaccine response in Immune-Compromised patients
Knowledge-focused CompletedThis study looked at how people with autoimmune diseases like multiple sclerosis or blistering skin conditions respond to COVID-19 vaccines while on B-cell depleting therapies. Researchers measured antibody levels and T-cell activity over time to understand vaccine effectiveness …
Matched conditions: NEUROMYELITIS OPTICA
Sponsor: Yale University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC